T Cell News and Research

Latest T Cell News and Research

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

OncoGenex commences custirsen Phase 3 trial in non-small cell lung cancer

OncoGenex Pharmaceuticals, Inc. announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed.

28 Sep 2012

Hundreds of new genes are involved in function and development of T-cells

A research team led by investigators at New York University and NYU School of Medicine has determined how cells that cause inflammatory ailments, such as Crohn's disease, multiple sclerosis, and arthritis, differentiate from stem cells and ultimately affect the clinical outcome of these diseases.

27 Sep 2012

George Mason University research makes big breakthrough in HIV

New research showing how the HIV virus targets "veterans" or memory T-cells could change how drugs are used to stop the virus, according to new research by George Mason University.

27 Sep 2012

Key bacterial protein structures reveal one of the biochemical secrets behind multi-drug tolerance

The structures of key bacterial proteins have revealed one of the biochemical secrets that enables bacteria to outwit antibiotics.

27 Sep 2012

Social media sites let chronically ill teens be teens

Most chronically ill teenage patients do not disclose their personal health information on social media websites such as Facebook, research shows.

27 Sep 2012

DNp63a protein employs epigenetics to keep cancer cells alive

Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.

27 Sep 2012

MicroRNA processing in fat tissue plays a major role in aging and stress resistance

As part of their ongoing research investigating the biology of aging, the greatest risk factor for type 2 diabetes and other serious diseases, scientists at Joslin Diabetes Center have identified a new factor - microRNA processing in fat tissue - which plays a major role in aging and stress resistance.

27 Sep 2012

Study characterizes movement of rhodopsin

A recent study in The Journal of General Physiology characterizes the movement of rhodopsin, a GPCR and member of a large family of transmembrane receptors responsible for many cellular responses and involved in many human diseases.

27 Sep 2012

New understanding about functionality of CFTR protein

CFTR is an important protein that, when mutated, causes the life-threatening genetic disease cystic fibrosis. A study in The Journal of General Physiology (JGP) details how an accidental discovery has provided new understanding about CFTR functionality.

27 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Adult stem cells can prevent Alzheimer's disease

In the first study of its kind, researchers at Korea's leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer's disease, they can prevent the disease.

27 Sep 2012

Tight-junction proteins could help pin down hemorrhagic transformation risk

Study findings suggest that measuring levels of tight-junction proteins in the blood of patients with stroke may help to gauge their risk for hemorrhagic transformation.

26 Sep 2012

Wheeze predicts sickle cell disease crisis

Wheezing is a significant indicator for morbidity in patients with sickle cell disease, US researchers believe.

26 Sep 2012

Increasing doses of radium chloride effective, tolerated in prostate cancer

Radium chloride treatment has dose-dependent beneficial effects on health outcomes in patients with castration-resistant prostate cancer and bone metastases, report researchers.

26 Sep 2012

Blood test for monitoring Huntington’s disease may be possible in future

Measuring blood levels of mutant huntingtin protein may provide an alternative approach of determining the onset of Huntington’s disease in known carriers, researchers report.

26 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

CivaTech Oncology receives NIH/NCI Phase II Contract for CivaSheet device to treat NSCLC

CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer.

26 Sep 2012

Cell Banker 3 cryopreservation solution effectively preserves iPSCs

In a study to determine the best cryopreservation (freezing) solution to maintain induced pluripotent stem (iPS) cells, a team of researchers from Japan compared 12 kinds of commercially prepared and readily available cryopreservation solutions and found that "Cell Banker 3" out-performed the other 11 solutions by allowing iPS cells to be preserved for a year at -80 degrees C in an undifferentiated state.

26 Sep 2012

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

The good news widely reported this morning of positive results from a clinical drug trial at Boston Children's Hospital for the previously "untreatable" rapid aging disorder in children known as progeria has its scientific roots in basic biology discoveries made in recent years.

26 Sep 2012